12-11-2018

Prof. Dr. H. Lode; Immunotherapy Subcommittee
List of Publications in connection with SIOPEN since 2000

2018

1. Ceylan K, Jahns LJ, Lode BN, Ehlert K, Kietz S, Troschke-Meurer S, Siebert N, Lode HN.
   Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.
   Pediatr Blood Cancer. 2018 Jan 19. doi: 10.1002/pbc.26967. [Epub ahead of print]

2. Siebert N, Troschke-Meurer S, Marx M, Zumpe M, Ehlert K, Gray J, Garaventa A, Manzitti C, Ash S, Klingebiel T, Beck J, Castel V, Valteau-Couanet D, Loibner H, Ladenstein R, Lode HN. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
   Cancers (Basel). 2018 Oct 17;10(10). pii: E387. doi: 10.3390/cancers10100387.

3. Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Isaac Yaniv, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, Toby Trahair, Godfrey Chi Fung Chan, Ellen Ruud, Henrik Schroeder, Maja Beck Popovic, Guenter Schreier, Hans Loibner, Peter Ambros, Keith Holmes, Maria Rita Castellani, Mark N. Gaze, Alberto Garaventa, Andrew DJ Pearson, Holger N. Lode
   Multi-centre, randomised, phase 3 trial of Interleukin-2 with anti-GD2 Antibody ch14.18/CHO (dinutuximab beta) in High-Risk Neuroblastoma Patients. Results from the HR-NBL1/SIOPEN Trial.
   The Lancet Oncology 2018 (Published online November 12th 2018)

2017

4. Ina Mueller, Karoline Ehlert, Stefanie Endres, Lena Pill, Nikolai Siebert, Silke Kietz, Penelope Brock, Alberto Garaventa, Dominique Valteau-Couanet, Evelyne Janzek, Norbert Hosten, Andreas Zinke, Winfried Barthlen, Emine Varol, Hans Loibner, Ruth Ladenstein, Holger N. Lode'
   Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO
   MAbs. 2018 Jan;10(1):55-61. doi: 10.1080/19420862.2017.1402997. Epub 2017 Dec 5.

5. Siebert N, Zumpe M, Jüttner M, Troschke-Meurer S, Lode HN
   PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO
   OncoImmunology, 6:10, e1343775, DOI: 10.1080/2162402X.2017.1343775

2016

6. Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Jüttner M, Ehlert K, Kietz S, Müller I, Lode HN
   Neuroblastoma patients with high affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
   Oncoimmunology. 2016 Sep 26;5(11):e1235108. doi: 10.1080/2162402X.2016.1235108. eCollection 2016.

7. Siebert N, Eger C, Seidel D, Jüttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, Weiss M, Loibner H, Ladenstein R, Lode HN

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long term infusion in combination with IL-2
MAbs. 2016 Apr;8(3):604-16. doi: 10.1080/19420862.2015.1130196. Epub 2016 Jan 19

2014

8. Siebert N, Seidel D, Eger C, Jüttner M, Lode HN
Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.
PLOS ONE, September 2014 | Volume 9 | Issue 9 | e107692

9. Siebert N, Eger C, Seidel D, Jüttner M, Lode HN.
Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
J Immunol Methods. 407:108-15 2014.

10. Chowdhury F, Lode HN, Cragg MS, Glennie MJ, Gray JC.
Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood.
Cancer Immunol Immunother. 63, 559-69, 2014.

2013

11. Siebert N, Seidel D, Eger C, Brackrock D, Reker D, Schmidt M, Lode HN.
Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
J Immunol Methods. 15, 398-399, 2013.

12. Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V, Michon J, Garaventa A, Lode HN.
Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.
MAbs. 5, 801-9, 2013

2005

13. Y. Zeng, S. Fest, R. Kunert, H. Katinger, V. Pistoia, J. Michon, G. Lewis, R. Ladenstein, H.N. Lode
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice
Molecular Immunology, 42, 1311-1319, 2005.